159 related articles for article (PubMed ID: 37957414)
1. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.
Cook DP; Galpin KJC; Rodriguez GM; Shakfa N; Wilson-Sanchez J; Echaibi M; Pereira M; Matuszewska K; Haagsma J; Murshed H; Cudmore AO; MacDonald E; Tone A; Shepherd TG; Petrik JJ; Koti M; Vanderhyden BC
Commun Biol; 2023 Nov; 6(1):1152. PubMed ID: 37957414
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
3. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
Russell S; Lim F; Peters PN; Wardell SE; Whitaker R; Chang CY; Previs RA; McDonnell DP
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077756
[TBL] [Abstract][Full Text] [Related]
4. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.
McCloskey CW; Goldberg RL; Carter LE; Gamwell LF; Al-Hujaily EM; Collins O; Macdonald EA; Garson K; Daneshmand M; Carmona E; Vanderhyden BC
Front Oncol; 2014; 4():53. PubMed ID: 24672774
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
6. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
7. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
8. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.
Maniati E; Berlato C; Gopinathan G; Heath O; Kotantaki P; Lakhani A; McDermott J; Pegrum C; Delaine-Smith RM; Pearce OMT; Hirani P; Joy JD; Szabova L; Perets R; Sansom OJ; Drapkin R; Bailey P; Balkwill FR
Cell Rep; 2020 Jan; 30(2):525-540.e7. PubMed ID: 31940494
[TBL] [Abstract][Full Text] [Related]
9. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
10. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.
Denisenko E; de Kock L; Tan A; Beasley AB; Beilin M; Jones ME; Hou R; Muirí DÓ; Bilic S; Mohan GRKA; Salfinger S; Fox S; Hmon KPW; Yeow Y; Kim Y; John R; Gilderman TS; Killingbeck E; Gray ES; Cohen PA; Yu Y; Forrest ARR
Nat Commun; 2024 Apr; 15(1):2860. PubMed ID: 38570491
[TBL] [Abstract][Full Text] [Related]
11. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
12. The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
Leinster DA; Kulbe H; Everitt G; Thompson R; Perretti M; Gavins FN; Cooper D; Gould D; Ennis DP; Lockley M; McNeish IA; Nourshargh S; Balkwill FR
J Pathol; 2012 Jun; 227(2):136-45. PubMed ID: 22322968
[TBL] [Abstract][Full Text] [Related]
13. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.
Rodriguez GM; Galpin KJC; Cook DP; Yakubovich E; Maranda V; Macdonald EA; Wilson-Sanchez J; Thomas AL; Burdette JE; Vanderhyden BC
Cancer Res Commun; 2022 Jun; 2(6):417-433. PubMed ID: 36311166
[TBL] [Abstract][Full Text] [Related]
15. Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78.
Mo L; Bachelder RE; Kennedy M; Chen PH; Chi JT; Berchuck A; Cianciolo G; Pizzo SV
Mol Cancer Ther; 2015 Mar; 14(3):747-56. PubMed ID: 25589495
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
17. FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
Lai H; Zhao X; Qin Y; Ding Y; Chen R; Li G; Labrie M; Ding Z; Zhou J; Hu J; Ma D; Fang Y; Gao Q
J Exp Clin Cancer Res; 2018 Feb; 37(1):32. PubMed ID: 29458390
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
19. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
